Maximum inflation of the type 1 error rate when sample size and allocation rate are adapted in a pre-planned interim look

Statistics in Medicine

Volumn 30, Issue 14, 2011, Pages 1637-1647

  Graf, Alexandra C ^a   Bauer, Peter ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Changing allocation rates; Conditional error function; Interim analysis; Maximum type 1 error rate; Sample size reassessment; Z test

Indexed keywords

ALLOCATION RATE; ARTICLE; CONTROL GROUP; MAXIMUM TYPE 1 ERROR RATE; NORMAL DISTRIBUTION; NULL HYPOTHESIS; OUTCOME VARIABLE; SAMPLE SIZE; SAMPLING; SAMPLING ERROR; STATISTICAL ANALYSIS;

ALGORITHMS; BIAS (EPIDEMIOLOGY); HUMANS; MODELS, STATISTICAL; NORMAL DISTRIBUTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SAMPLE SIZE; TREATMENT OUTCOME;

EID: 79957950338     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.4230     Document Type: Article

References (18)

1. Proschan MA, Hunsberger SA. Designed extension of studies based on conditional power. Biometrics 1995; 51:1315-1324.
2. Bauer P. Multistage testing with adaptive designs. Biometrie und Informatik in Medizin und Biologie 1989; 20:130-148.
3. Bauer P, Koehne K. Evaluations of experiments with adaptive interim analysis. Biometrics 1994; 50:1029-1041.
4. Lehmacher W, Wassmer G. Adaptive sample size calculations in group sequential trials. Biometrics 1999; 55:1286-1290.
5. Brannath W, Posch M, Bauer P. Recursive combination tests. JASA 2002; 97:236-244.
6. Mueller HH, Schaefer H. Adaptive group sequential designs for clinical trials: combining the advantages of adaptive and of classical group sequential approaches. Biometrics 2001; 95:886-891.
7. Mueller HH, Schaefer H. A general statistical principle for changing a design any time during the course of a trial. Statistics in Medicine 2004; 23:2497-2508.
8. Proschan MA. Sample size re-estimation in clinical trials. Biometrical Journal 2009; 51:348-357.
9. Posch M, Timmesfeld N, Koenig F, Mueller HH. Conditional rejection probabilities of students t-test and design adaptations. Biometrical Journal 2004; 46:389-403.
10. Timmesfeld N, Schaefer H, Mueller HH. Increasing the sample size during clinical trials with t-distributed test statistics without inflating the type I error rate. Statistics in Medicine 2006; 26:2449-2464.
11. Gutjahr G, Brannath W, Bauer P. A general approach to the conditional error rate principle with nuisance parameters. Biometrics 2010; DOI: 10.1111/j.1541.
12. Committee for Proprietary Medical Products (CPMP). Statistical principles for clinical trials. 1998; CPMP/ICH/ 363/96.
13. Committee for Medicinal Products for Human Use (CHMP). Reflection paper on methodological issues in confirmatory clinical trials planned with an adaptive design. 2007; CHMP/EWP/2459/02.
14. Friede T, Henderson R. Exploring changes in treatment effects across design stages in adaptive trials. Pharmaceutical Statistics 2009; 8:62-72.
15. Hu F, Rosenberger WF. The Theory of Response-daptive Randomization in Clinical Trials. Wiley: New Jersey, 2006.
16. Hung HM, Wang SJ, O'Neill RT. Challenges and regulatory experiences in non-inferiority trial design without placebo arm. Biometrical Journal 2009; 51:324-334.
17. Brannath W, Koenig F, Bauer P. Estimation in flexible two stage designs. Statistics in Medicine 2006; 25:3366-3381.
18. Stallard N. A confirmatory seamless phase II/III clinical trial design incorporating short-term endpoint information. Statistics in Medicine 2009; 29:959-971.